華領醫藥hms5552單藥治療iii期臨床試驗完成所有受試者入組
March 01, 2019 01:00 ET
|
Hua Medicine
上海, March 01, 2019 (GLOBE NEWSWIRE) -- 華領醫藥技術（上海）有限公司（以下簡稱「華領醫藥」，香港主機板股票代碼：2552）是一家專注於研發治療全球2型糖尿病原創口服新藥的生物技術公司。今天華領醫藥宣佈HMS5552（dorzagliatin）單藥治療的III期臨床試驗完成受試者入組，並預計將於2019年第四季度公佈最新試驗結果。 ...
华领医药hms5552单药治疗iii期临床试验完成所有受试者入组
March 01, 2019 01:00 ET
|
Hua Medicine
上海, March 01, 2019 (GLOBE NEWSWIRE) -- 华领医药技术（上海）有限公司（以下简称「华领医药」，香港主板股票代码：2552）是一家专注于研发治疗全球2型糖尿病原创口服新药的生物技术公司。今天华领医药宣布HMS5552（dorzagliatin）单药治疗的III期临床试验完成受试者入组，并预计将于2019年第四季度公布最新试验结果。 ...
Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliatin
March 01, 2019 01:00 ET
|
Hua Medicine
SHANGHAI, China, March 01, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (HKEX: 2552), a Shanghai-based drug development company focused on developing a global first-in-class oral drug for the treatment of...
華領醫藥於美國開展首項Dorzagliatin與DPP-4 抑制劑聯合用藥的研究
January 31, 2019 23:34 ET
|
Hua Medicine
上海, Feb. 01, 2019 (GLOBE NEWSWIRE) --...
华领医药于美国开展首项Dorzagliatin与DPP-4 抑制剂联合用药的研究
January 31, 2019 23:34 ET
|
Hua Medicine
上海, Feb. 01, 2019 (GLOBE NEWSWIRE) --...
Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States
January 31, 2019 23:34 ET
|
Hua Medicine
SHANGHAI, China, Jan. 31, 2019 (GLOBE NEWSWIRE) -- Hua Medicine (“Hua” or “the Company”; Stock Code: 2552.HK) a Shanghai-based drug development company focused on developing a global first-in-class...
華領醫藥在 D 輪和 E 輪融資中募集資金 1.174 億美元
March 26, 2018 20:00 ET
|
Hua Medicine
中國香港、上海, March 27, 2018 (GLOBE NEWSWIRE) -- 華領醫藥，一家致力於開發突破性原創新藥的臨床階段藥物開發公司，宣佈完成 D 輪和 E 輪融資，共募集資金 1.174 億美元。投資者包括新投資方 Blue Pool Capital Limited、GIC Private Limited、航信環球、通和毓承、鄭志剛（通過 K11...
华领医药在 D 轮和 E 轮融资中募集资金 1.174 亿美元
March 26, 2018 20:00 ET
|
Hua Medicine
中国香港、上海, March 27, 2018 (GLOBE NEWSWIRE) -- 华领医药，一家致力于开发突破性原创新药的临床阶段药物开发公司，宣布完成 D 轮和 E 轮融资，共募集资金 1.174 亿美元。投资者包括新投资方 Blue Pool Capital Limited、GIC Private Limited、航信环球、通和毓承、郑志刚（通过 K11...
Hua Medicine Raises $117.4 Million in Series D & Series E Financing
March 26, 2018 20:00 ET
|
Hua Medicine
HONG KONG and SHANGHAI, China, March 26, 2018 (GLOBE NEWSWIRE) -- Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced...
Bank of America Merrill Lynch Investment Banking Veteran Joins Hua Medicine as CFO
December 21, 2017 19:00 ET
|
Hua Medicine
SHANGHAI, China, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced George Lin, a seasoned investment banker in the U.S. and...